Please login to the form below

Not currently logged in
Email:
Password:

hypoglycaemia

This page shows the latest hypoglycaemia news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk spends $800m on biotech and 'glucose responsive insulin' tech

Novo Nordisk spends $800m on biotech and 'glucose responsive insulin' tech

Combining this technology with Novo Nordisk’s insulin to create GRIs would ultimately help further its goal of eliminating the risk of hypoglycaemia, the main risk associated with insulin therapy. ... have the potential to lead to the development of

Latest news

More from news
Approximately 2 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    end of last year and has demonstrated it is as effective in reducing blood glucose levels as is its rival Lantus from Sanofi, yet carries less risk of hypoglycaemia. ... In addition, Meeus highlighted a need to raise awareness among the healthcare

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    2 diabetes further reduce HbA1c, with the benefit of weight loss and limited risk of hypoglycaemia.”.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How technology is shaping patient education

    The simulation showed the high impact of mild hypoglycaemia (low blood sugar) on a patient; it made the viewer ‘ feel’ the symptoms of hypoglycaemia in various scenarios through a typical day

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics